{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T02:22:46Z","timestamp":1786760566908,"version":"build-2736575974"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We evaluated the maintenance of virological suppression in people living with multidrug resistance (MDR) HIV (PLWH), who simplified to bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a prospective, observational study of 62 PLWH with MDR who switched therapy because of drug\u2013drug interactions (DDIs), non-adherence or toxicity. Survival analysis was used to assess the probability of virological failure (VF). Cumulative genotypic susceptibility score to BIC\/FTC\/TAF (cGSS; maximum 3 points) was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Before the switch, PLWH were virologically suppressed for a median of 7.95 years (interquartile range, IQR, 2.5\u20139.7), 60% and 37% had resistance to two and three classes of antiretrovirals respectively (median cGSS = 2), and the mutation M184V\/I was observed in 34 cases (68%). The main reason for switching was DDIs (61%). At Week 48, there were no VFs, three patients (5%) discontinued early due to mild neuropsychiatric events, and two showed transient detectable HIV RNA levels (1.8 and 1.85 log copies\/mL). Thus, the efficacy was 91% (95% CI, 81%\u201399%, intention-to-treat analysis) and 94% (95% CI, 87%\u2013100%, on-treatment). Total cholesterol and LDL cholesterol decreased significantly after the switch, and estimated glomerular filtration rate and tubular parameters remained stabilized. Excluding two diabetic PLWH with progressive renal deterioration, there were no VFs or additional discontinuations for 32.5 months (IQR, 14.1\u201348.5; follow-up, 199 person-years). By survival analysis, the probability of remaining on BIC\/FTC\/TAF was 91% at 5 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In highly treatment-experienced PLWH harbouring MDR strains, who were virologically suppressed, switching to BIC\/FTC\/TAF was well tolerated with maintenance of virological control.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf357","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T11:38:09Z","timestamp":1757417889000},"page":"3242-3247","source":"Crossref","is-referenced-by-count":2,"title":["From TRIO to one: simplification to bictegravir\/emtricitabine\/tenofovir alafenamide in highly treatment-experienced people living with MDR HIV"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7639-8591","authenticated-orcid":false,"given":"Jos\u00e9 L","family":"Casado","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Ramon y Cajal Hospital , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L","family":"Blanco","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Clinic Hospital , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Izuzquiza","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Ramon y Cajal Hospital , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4407-3864","authenticated-orcid":false,"given":"Ana","family":"Moreno","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Ramon y Cajal Hospital , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8553-6995","authenticated-orcid":false,"given":"Pilar","family":"Vizcarra","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Ramon y Cajal Hospital , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Vallejo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Ramon y Cajal Hospital , Madrid ,","place":["Spain"]},{"name":"Laboratory of Immunovirology, Instituto Ram\u00f3n y Cajal de Investigaciones Sanitarias (IRyCIS), Ramon y Cajal Hospital , Madrid ,","place":["Spain"]},{"name":"Spanish Biomedical Research Center Network in Infectious Diseases (CIBERINFEC)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"2025120206224318300_dkaf357-B1","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1097\/QAD.0000000000002679","article-title":"Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options","volume":"34","author":"Bajema","year":"2020","journal-title":"AIDS"},{"key":"2025120206224318300_dkaf357-B2","doi-asserted-by":"publisher","first-page":"106696","DOI":"10.1016\/j.ijantimicag.2022.106696","article-title":"Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: towards drug-reduced regimen? ANRS CO3 aquitaine cohort 2007\u20132018","volume":"61","author":"Nyamankolly","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2025120206224318300_dkaf357-B3","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1080\/14740338.2020.1764531","article-title":"Nothing is perfect: the safety issues of integrase inhibitor regimens","volume":"19","author":"Scevola","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"2025120206224318300_dkaf357-B4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/cid\/ciz811","article-title":"Polypharmacy and drug-drug interactions in people living with human immunodeficiency virus in the region of Madrid, Spain: a population-based study","volume":"71","author":"Lopez-Centeno","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025120206224318300_dkaf357-B5","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/hiv.13650","article-title":"Prevalence of people living with multidrug-resistant HIV and limited treatment options in Spain","volume":"25","author":"Llibre","year":"2024","journal-title":"HIV Med"},{"key":"2025120206224318300_dkaf357-B6","doi-asserted-by":"publisher","first-page":"106956","DOI":"10.1016\/j.ijid.2024.01.023","article-title":"Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options\u2014the ICONA Foundation Cohort Study","volume":"143","author":"Lo Caputo","year":"2024","journal-title":"Int J Infect Dis"},{"key":"2025120206224318300_dkaf357-B7","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"2025120206224318300_dkaf357-B8","doi-asserted-by":"publisher","first-page":"101991","DOI":"10.1016\/j.eclinm.2023.101991","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials","volume":"59","author":"Sax","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2025120206224318300_dkaf357-B9","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1097\/QAD.0000000000003244","article-title":"High efficacy of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in people with suppressed HIV and preexisting M184V\/I","volume":"36","author":"Sax","year":"2022","journal-title":"AIDS"},{"key":"2025120206224318300_dkaf357-B10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/QAI.0000000000002454","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) from dolutegravir (DTG)+F\/TAF or DTG+ F\/tenofovir disoproxil fumarate (TDF) in the presence of pre-existing NRTI resistance","volume":"85","author":"Acosta","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025120206224318300_dkaf357-B11","doi-asserted-by":"publisher","first-page":"ofaf087","DOI":"10.1093\/ofid\/ofaf087","article-title":"Three-year effectiveness of bictegravir\/emtricitabine\/tenofovir alafenamide as a switch strategy in the real world","volume":"12","author":"de Gea-Grela","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2025120206224318300_dkaf357-B12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2025120206224318300_dkaf357-B13","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2025120206224318300_dkaf357-B14","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection","volume":"386","author":"Segal-Maurer","year":"2022","journal-title":"N Engl J Med"},{"key":"2025120206224318300_dkaf357-B15","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","article-title":"Fostemsavir in adults with multidrug-resistant HIV-1 infection","volume":"382","author":"Kozal","year":"2020","journal-title":"N Engl J Med"},{"key":"2025120206224318300_dkaf357-B16","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"2025120206224318300_dkaf357-B17","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"2025120206224318300_dkaf357-B18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12985-025-02648-3","article-title":"Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance\u2014a phase IV randomised, open-label study (PIBIK study)","volume":"22","author":"Iwuji","year":"2025","journal-title":"Virol J"},{"key":"2025120206224318300_dkaf357-B19","doi-asserted-by":"publisher","first-page":"e27330","DOI":"10.1097\/MD.0000000000027330","article-title":"Real-world efficacy and safety of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in older people living with HIV","volume":"100","author":"Rolle","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"2025120206224318300_dkaf357-B20","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1093\/jac\/dkae138","article-title":"Effectiveness, safety and discontinuation rates of bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) in people with HIV using real-world data: a systematic review and meta-analysis","volume":"79","author":"Chivite","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2025120206224318300_dkaf357-B21","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1097\/QAD.0000000000003311","article-title":"Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir\/emtricitabine\/tenofovir alafenamide in treatment experienced patients","volume":"36","author":"Mican","year":"2022","journal-title":"AIDS"},{"key":"2025120206224318300_dkaf357-B22","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1128\/AAC.47.11.3478-3484.2003","article-title":"Tenofovir resistance and resensitization","volume":"47","author":"Wolf","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206224318300_dkaf357-B23","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1086\/381784","article-title":"Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients","volume":"189","author":"Miller","year":"2004","journal-title":"J Infect Dis"},{"key":"2025120206224318300_dkaf357-B24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/jmv.20359","article-title":"Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients","volume":"76","author":"Wirden","year":"2005","journal-title":"J Med Virol"},{"key":"2025120206224318300_dkaf357-B25","doi-asserted-by":"publisher","first-page":"ofy113","DOI":"10.1093\/ofid\/ofy113","article-title":"Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: a cohort study","volume":"5","author":"Gagliardini","year":"2018","journal-title":"Open Forum Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3242\/64480875\/dkaf357.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3242\/64480875\/dkaf357.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T11:22:49Z","timestamp":1764674569000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/12\/3242\/8271844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":25,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,10,3]]},"published-print":{"date-parts":[[2025,12,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf357","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,3]]}}}